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Background: It is debated whether early treatment with inhaled corticosteroids (ICS) can
change the natural course of childhood asthma.
Aim: To assess if ICS treatment before 2 years of age in children with obstructive airways
disease reduces current asthma at 10 years of age.
Methods: Children with (n ¼ 233) and without (n ¼ 219) recurrent (r) bronchial
obstruction (BO) attending clinical examination at 2 years of age in the birth cohort
Environment and Childhood Asthma study in Oslo, were reinvestigated at 10 years of age.
Current asthma (CA) at 10 years was defined as asthma with either symptoms and/or
asthma treatment during the last year, and/or X10% fall in forced expired volume in 1 s
after standardized treadmill run. The risk of CA was assessed by logistic regression and
propensity modelling (including gender, parental atopy and severity score at 2 years) in
children with rBO who received ICS or not by 2 years.
Results: CA was found in 97 children, more often among rBO children with (56.9%) and
without ICS treatment (30.8%) compared to no-BO children (5.5%) (po0.001). In rBO
children logistic regression analyses (adjusted odds ratio aOR (95% confidence interval))
identified male gender (aOR 1.82 (1.01–3.27), p ¼ 0.046) and severity score at 2 years 1.14
(1.03–1.28), (p ¼ 0.01), as significant and ICS treatment as non-significant 2.00
(0.98–4.12) risk factors for CA. With propensity modelling adjusting for disease severity,Elsevier Ltd. All rights reserved.
ORAACLE (the Oslo Research Group of Asthma and Allergy in Childhood; the Lung and Environment), a
and Asthma European Network).
n, Department of Paediatrics, Rikshospitalet—Radiumhospitalet Medical center, Ullveien 14, NO 0791
: +47 22 13 65 05.
in.uio.no (K.-H. Carlsen).
ARTICLE IN PRESS
C.S. Devulapalli et al.1626ICS treatment by 2 years caused a non-significant increased risk aOR of CA of 1.84
(0.89–3.82).
Conclusion: No evidence was found that early use of ICS before age two in children with
rBO reduces current asthma 8 years later.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are the preferred long-term
controller medication for persistent asthma based on
their anti-inflammatory properties and significant evidence
of efficacy.1 Regular use of ICS has been reported, especially
during the early stages of asthma, to improve control
of symptoms and lung function in children 5–10 years of
age,2 and lung function in early childhood.3,4 Efficacy
has also been shown by stopping medication, as patients
frequently experience an exacerbation of their asthma
upon withdrawal of ICS, as shown both in pre-school and
school children,5,6 whilst regular use of low dose ICS
prevents asthma deaths as shown in a study including
subjects from 5 to 44 years of age.7 It has been stated that
about two-thirds of mildly asthmatic children outgrow their
disease, while the last third with more severe asthma will
have persistent symptoms in adult life.8 However, a study of
bronchial biopsies in subjects with asthma remission for
more than 3 years suggests that asthma might persist
throughout life.9
Recently, two randomized double-blind placebo-con-
trolled studies5,10 covering different parts of the preschool
age reported that symptom control and improved lung
function obtained during ongoing treatment with inhaled
steroids, were reduced after stopping treatment, and the
authors of both papers concluded that use of inhaled
steroids did not seem to influence the long-term prognosis
of asthma.5,10 A Danish study reported no influence on the
progression from episodic to persistent wheeze, with
intermittent treatment during episodes of wheezing from
infancy to the age of 3 years.11
Randomized controlled trials are generally considered the
best study designs to assess treatment efficacy, but are
associated with high costs, selected populations and are
often logistically difficult to maintain for many years. Thus,
an alternative for studying long-term outcome is by use of
prospective longitudinal observational cohorts.
Employing propensity score assessment in statistical
analyses has been proposed as a method to adjust for bias
in treatment assignment that may be present in observa-
tional studies.12 The propensity score provides an estimate
of the likelihood that the patient would receive treatment
based only on the values of individual covariates (which, for
asthma, would include factors such as gender, parental
atopy, atopic dermatitis and severity of illness) and adjust
for that the use of ICS for childhood asthma serves merely as
a marker of asthma severity.
In a recent article, we reported that 21% of children with
recurrent (r) bronchial obstruction (BO) received ICS by 2
years of age in the Environment and Childhood Asthma (ECA)
study in Oslo, an observational birth cohort study estab-lished in 1992/1993.3 The main objective of the present
study was to assess if ICS treatment by 2 years of age
influenced current asthma occurrence at 10 years of age.
Methods and subjects
Study design
The present study is a part of the 10-year follow-up of the
prospective birth cohort study, the ECA-study in Oslo.13
Briefly, a cohort of 3754 newborn babies was established at
birth in Oslo during 15 months starting from January 1992.
Written informed consent was obtained from parents of all
subjects upon enrolment. The study was approved by the
Regional Committee for Medical Ethics and the Norwegian
Data Inspectorate. The overall design of the birth cohort is
described elsewhere.13,14
To identify children with BO, parents of all children
completed half-yearly questionnaires from birth to their
child’s second birthday. Questions included: health of the
child (respiratory, allergic, skin as well as general diseases)
and details of all types of medical treatment, family history
of allergic and other diseases, parental socio-economic
status and environmental exposures as parental smoking
habits. Additionally, clinical signs of BO and treatment were
recorded in a check-box card by attending doctors at any
respiratory illnesses and returned to the study personnel at
the latest every 6 months.
A nested case-control study was established3,13,15 before
2 years of age to compare all children with at least two
episodes of doctor confirmed BO or minimum 4 weeks of
persistent BO by their second birthday (rBO) (n ¼ 306)14 to
control subjects without symptoms or signs of BO (no-BO)
(n ¼ 306). The 2-year detailed clinical examination was
attended by 516 of 612 eligible children, 265 rBO children
and 251 no-BO children, respectively (Fig. 1).
The 10-year follow-up study (September 2001–August
2004) included 239 of the rBO and 220 of the no-BO children
from the nested case control study at 2 years of age
(attendance rate 89%) (Fig. 1).
Subjects
Of the 459 children who attended both 2- and 10-year
follow-up visits (Fig. 1), 452 (245 boys and 207 girls) had
sufficient data to assess current asthma at 10 years of age.
The seven excluded subjects did not differ from the
remaining children regarding baseline demographic data
and parental atopy, but were significantly heavier at 10
years (data not shown). Mean age (standard deviation (SD))
at the 10-year visit was 10.3 (0.7) years. Demographic data
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Figure 1 Flow chart of the study subjects participating in the
examinations in the Environment and Childhood Asthma study.
Children with rBO were children with recurrent bronchial
obstruction by 2 years of age (for definition see Methods). No
BO children were age-matched children without bronchial
obstruction by 2 years of age.
Inhaled steroids in early childhood asthma 1627of the 452 children are given in Table 1. Fifty-one (21.9%)
rBO children reported use of ICS between 0 and 2 years
of age, whereas the remaining 182 rBO children and none
of the control subjects received ICS during these years
(Table 2). Mean (SD) duration of ICS therapy until two years
was 8.5 (5.9) months (range 1–22 months). Allergic
sensitisation, parental atopy and atopic eczema were
similar at 2 years among rBO children who did and did
not receive ICS treatment by 2 years (Table 1), whereas
atopic eczema and parental atopy were more frequently
reported among ICS-treated rBO children than no-BO
children (Table 1). The rBO children who had not received
ICS treatment 0–2 years frequently reported parental atopy
and were slightly younger than no-BO children at the 2 years
visit (Table 1).
Methods
Two-year visit
At the 2-year clinical visit, a parental structured interview
was completed regarding diseases of the index child and
primary family members, infections, tobacco-exposure,
housing, socio-economic factors and medical treatment.
The questions regarding BO are described in full else-
where.16 Additionally, the following questions regarding
treatment of rBO were asked: ‘‘the use of preventive
or regular therapy for wheezing?,’’ if yes, ‘‘the use of
ICS as regular therapy?’’ if yes, questions regarding age
at start, duration and age at cessation of ICS therapy were
asked.
Skin Prick test (SPT) was performed according to the
Nordic standard17 to the following allergens: cow’s milk, andthe following standardized allergen extracts (ALK SQ): egg
white, dermatophagoides (D.) pteronyssinus, timothy
grass, cat dander, dog dander, silver birch, mugwort and
cladosporium herbarum, as well as negative control solution
and histamine control (10mg/ml). Sensitization was re-
garded as positive with a wheal for the allergen in question
of at least half the size of wheal for the histamine positive
control.
Parental atopy by 2 years of age was defined as asthma
and/or rhinoconjunctivitis reported in at least one parent.
Ten-year follow-up visit
At the 10-year visit,14 study doctors conducted parental
structured interview regarding symptoms of asthma, asthma
management with particular focus on ICS treatment, and
other allergic diseases, including validated translated into
Norwegian International Study of Asthma and Allergies in
Children (ISAAC) questions.18
Forced expiratory flow volume loops was measured
according to European standard19 (reference values of
Zapletal20 with a SensorMedics Vmax 20c (SensorMedics
Diagnostics, Yorba Linda, California, USA).
Exercise induced bronchoconstriction was assessed by
running for 6–8min on a motor driven treadmill (Woodways
GmbH, Weil am Rhein, Germany) (inclination of 5.5%),
with increasing speed during the first minutes to reach
a heart rate of 95% of estimated maximum for the last
4min.21 Forced expiratory volume in 1 s (FEV1) was
measured before, and 3, 6, 10, 15 and 20min after
running as well as 10min after inhalation of nebulised
salbutamol (0.5mg per 10 kg bodyweight) administered
20min after running. The exercise test was considered
positive with X10% fall of baseline FEV1 3–20min after
running ceased.
A severity score (from 0 to 12, 0 being no-BO) to
determine severity of obstructive airways disease by 2 years
of age was calculated based upon the number of episodes
with BO, number of months with persistent BO and number
of hospital admissions due to BO (by 2 years), described in
detail previously.16
Outcome
The main outcome was the presence of current asthma (CA)
at 10 years of age.14
Asthma was defined by at least two of the following three
criteria being fulfilled:1. Dyspnoea, chest tightness and/or wheezing 0–3 years
and/or 4–10 years.2. Doctor’s diagnosis of asthma.
3. Use of asthma medication (b-2 agonist, sodium cromo-
glycate, corticosteroids, leukotriene antagonists and/or
aminophylline) 0–3 years and/or 4–10 years.
Current asthma was defined as asthma (by definition above)
plus at least one of the following:1. Dyspnoea, chest tightness and/or wheezing during the
last 12 months.
ARTICLE IN PRESS
Table 1 Demographic data of children with recurrent bronchial obstruction (rBO) (recurrent (X2) or persisting (X4 weeks)
doctor confirmed BO) and children without BO by 2 years of age.
Children with rBO (n ¼ 233) Children with
no-BO
(n ¼ 219)
p-
values
p-
values
ICS treatment
0–2 yr of age
(n ¼ 51)
No ICS
treatment
0–2 yr of age
(n ¼ 182)
p-values
between
treatment groups
of rBO children
Boys (n (%)) 31 (60.8) 109 (59.9) 0.91 105 (47.9) 0.09 0.10
Age(mean (SD))
2 yr visit (months) 25.8 (1.9) 26.1 (3.0) 0.46 27.7 (3.8) 0.0004 o0.0001
10 yr visit (years) 10.2 (0.7) 10.4 (0.7) 0.21 10.3 (0.8) 0.52 0.34
Weight (mean (SD))
2 yr visit (kg) 12.9 (1.6) 13.6 (1.4) 0.005y 13.4 (1.6) 0.075 0.18
10 yr visit (kg) 38.1 (9.6) 37.7 (7.4) 0.79 36.8 (7.6) 0.30 0.23
Height (mean (SD))
2 yr visit (cm) 87.6 (4.5) 89.6 (3.5) 0.005y 90.2 (4.2) 0.0001z 0.13
10 yr visit (cm) 141.7 (7.6) 144.3 (7.0) 0.024y 143.1 (7.5) 0.26 0.10
Allergic skin sensitization
at 2 yr visity (n (%))
6 (11.8) 16 (9.3) 0.61 17 (8.0) 0.50 0.99
Parental atopy by 2 yrz (n
(%))
26 (55.3) 92 (60.1) 0.56 51 (40.8) 0.18 0.07
Atopic eczema by 2 yr (n
(%))
25 (49.0) 63 (34.8) 0.065 60 (27.5) 0.02 0.45
The rBO children were dichotomized into children who received inhaled corticosteroids (ICS) or not between 0 and 2 years of age.
p-values when subjects with no-BO are compared with subjects who received ICS treatment by 2 years of age.
p-values when subjects with no-BO are compared with subjects without ICS treatment by 2 years of age.
yWeight at 2 years (but not height at two and 10 years) was statistically significant after adjusting for age and gender.
zHeight at 2 years was not statistically significant after adjusting for age and gender.
yAllergic skin sensitization considered positive withXone positive skin prick test to common allergens.
zParental atopy: asthma and/or allergic rhinitis reported in at least one parent.
C.S. Devulapalli et al.16282. Use of asthma medication (b-2 agonist, sodium cromo-
glycate, corticosteroids, leukotriene antagonists and/or
aminophylline) during the last 12 months.3. Positive exercise test.Statistical analyses
Demographic results are given either as mean with SD or
count with percentage. Differences between ICS treated and
ICS non-treated and subjects with no-BO by 2 years of age
were assessed using student t-tests for continuous variables,
whereas Pearson’s w2-test was used for categorical variables.
The risk of CA among rBO children with and without early
ICS treatment was assessed using logistic regression with and
without propensity modelling. Since several factors that
were expected to be associated with the use of ICS by 2
years could also be expected to affect later prognosis of the
disease, a propensity model22 was developed to adjust for
such factors. The model included gender, severity score, and
atopic dermatitis by 2 years as covariates. The appropriate-
ness of the logistic model was assessed using Hosmer and
Lemeshow Goodness-of-fit statistic.23 The results were given
as odds ratios (OR) with 95% confidence intervals (CI) in
parentheses.
All p-values equal to or below 0.05 were considered
statistically significant. Calculations were performed withStatistical Package for Social Sciences (SPSS) version 14.0 for
Windows.
Results
Current asthma at 10 years was significantly more frequent
among ICS-treated children (n ¼ 29) (56.9%) compared to
rBO children who were not ICS-treated (n ¼ 56) (30.8%) and
no-BO children (n ¼ 12) (5.5%) (po0.001).
Risk of CA
Logistic regression demonstrated in rBO children that male
gender (adjusted odds ratio (aOR): 1.82 (1.01–3.27),
p ¼ 0.046) and severity score at the age of 2 years (aOR
1.14 (1.03–1.28), p ¼ 0.014) were significant risk factors for
CA at the 10 years, whereas the use of inhaled steroids
before 2 years of age was non-significantly (borderline)
associated with CA (aOR 2.00 (0.98–4.12), p ¼ 0.058).
When modelling CA at 10 years of age for rBO children, we
used the propensity method to adjust for severity of disease
at 2 years of age. The propensity scores were based upon
gender, parental atopy and severity score at 2 years. The
analysis resulted in a non-significant aOR (95% CI) 1.842
(0.889–3.815), p ¼ 0.10, for the use of ICS compared to no
use before 2 years of age. In this model, the propensity score
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Table 2 Characteristics of subjects with current asthma at 10 years of age (n ¼ 97) according to the presence of recurrent
bronchial obstruction (rBO) (recurrent (41) or persisting (X4 weeks) doctor confirmed BO) and children without BO by two
years of age.
Children with current asthma at 10 yr of age
Children with rBO by 2 yr (n ¼ 85) p-values between
treatment groups
of rBO children
Children with no
BO by 2 yr
(n ¼ 12)ICS treatment 0–2
years of age
(n ¼ 29)
No ICS treatment
0–2 yr of age
(n ¼ 56)
Boys (n %) 17 (58.6) 41 (73.2) 0.17 11 (91.7)
Parental atopy by 2 yr (n %) 14 (48.3) 34 (35.7) 0.23 8 (87.5)y
Atopic dermatitis by 2 yr (n %) 14 (48.3) 24 (42.9) 0.63 5 (41.7)
Hospital admissions for BO 0–2 yr
(number of children) (n %)
19 (65.5) 20 (36.4) 0.011 n.a.
Number of hosp. admissions due to
BO 0–2 yr (mean 95% CI)
1.3 (0.8–1.8) 0.5 (0.3–0.7) 0.001 n.a.
Severity score by 2 yr of age (mean
95% CI)
7.5 (6.6–8.4) 4.5 (3.7–5.2) o0.001 n.a.
The rBO children were dichotomized into children who received inhaled corticosteroids (ICS) or not between 0 and 2 years of age.
p ¼ 0.006 comparing subjects with no BO to rBO subjects who received ICS by 2 years.
Parental atopy: asthma and/or allergic rhinitis reported in at least one parent. n.a: not applicable.
yp ¼ 0.035 when subjects with no BO are compared with subjects who received ICS treatment by 2 years of age.
Inhaled steroids in early childhood asthma 1629at 2 years of age was highly significantly associated with CA
at 10 years aOR 7.51 (1.70–33.21), p ¼ 0.008.
Two-year characteristics
Among children with CA, the rBO children with versus
those without ICS treatment by 2 years, had at 2 years
significantly higher severity scores and had significantly
more often been admitted to hospital due to BO (Table 2).
However, atopic eczema, parental atopy (Table 2) and
allergic skin sensitization (data not shown) did not differ
significantly between these children. Boys were over-
represented in all groups of children with current asthma
(69/97) (71%) (Table 2).
The rBO children who received ICS had slightly, but
significantly lower weight and height at 2 years compared to
rBO children who did not receive ICS, and age and height
was significantly lower compared to the no-BO children
(Table 1). However, the 2-year height was not significantly
different between ICS treated and no-BO children after
adjusting for age and gender.
Although height at 10 years in ICS-treated children was
significantly lower (p ¼ 0.034) than among rBO children
without ICS treatment, the difference was not significant
after adjustment for age and gender.
Discussion
In the present study, we found no evidence that early
use of ICS in children with rBO in the first 2 years of life
reduced the occurrence of current asthma at 10 years of
age.
This is to our knowledge, the first reported risk assess-
ment of early ICS treatment for CA 8 years later in anobservational birth cohort study, and using a propensity
model to adjust for risk factors that may influence later
outcome as well as induce treatment with ICS by 2 years of
age.
Our finding that ICS treatment before 2 years did not
reduce ongoing asthma at 10 years of age is supported by
recent reports of randomized placebo-controlled studies
with ICS treatment in early childhood with a follow-up to 3
and 5 years of age,5,10,11 as well as studies demonstrating
ongoing inflammation in bronchial biopsies from adolescents
despite asthma in remission, even after years with ICS
treatment.9 Furthermore, school children in a case-control
study treated for 28–36 months with ICS had symptom
improvement only during treatment while experiencing
recurring asthma symptoms after stopping ICS.6 On the
other hand, airways remodelling in children with recurrent
wheeze was not found in bronchial biopsies in children
below 3 years of age,24 and the concept of inflammatory
remodelling in early childhood is still unclear. Three recent
reports of ICS treatment in high-risk infants and pre-school
children all failed to demonstrate superior effect of ICS to
placebo on long-term outcome after cessation of treatment.
In the study of Bisgaard et al.11 of high-risk infants from 1
month of age, daily treatment of 400 mg budesonide for 2
weeks intermittently during wheezy episodes or cough was
no better than placebo to prevent persistent wheeze at 3
years of age. Using an asthma predictive index in children
with at least four wheezy episodes, Guilbert et al.5 reported
significant improvement during treatment in children with 2
years treatment of inhaled fluticasone propionate 88 mg
twice daily compared to placebo. However, after 1-year
follow-up after cessation of ICS treatment, there was no
longer significant improvement in asthma symptoms or
exacerbations. Very similar to the case definition in the
present study, Murray et al.10 treated 200 children with
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C.S. Devulapalli et al.1630prolonged (41 month) or recurrent wheeze (minimum two
medically confirmed episodes) with fluticasone 100 mg twice
daily or placebo and attempted three monthly treatment
reductions before eventual cessation of ICS treatment. After
a follow-up until 5 years of age, the authors concluded that
no effect of ICS was found on the natural history of asthma,
lung function decline or airways reactivity.10 Two of these
studies introduced treatment early,10,11 whereas Guilbert
et al.5 started treatment after 2 years of age.
On the other hand, early ICS therapy (within 2 years
of diagnosis) in older children with moderately severe
asthma, significantly improved lung function as well as
control of asthma compared to children starting ICS
therapy 5 years or later after the diagnosis of asthma.25
Also Merkus et al. reported improved lung function after
use of ICS in school children as compared to placebo.26
However, apart from the study of Guilbert et al.,5 Murray
et al.10 and the present study, little information of long-
term effects of ICS treatment during the first few years of
life is reported.
Although a systematic review by Calpin et al. concluded
that ICS were effective in controlling childhood asthma of all
ages,27 assessment of possible modifying effect of ICS upon
the natural course of asthma during childhood raises
important statistical issues. As was the case also in the
present study, it may be assumed that severity of disease at
an early stage may have an impact on the outcome of
asthma at 10 years of age,16 and we have recently reported
that the presence of asthma during school age may partly be
predicted by reduction in lung function already at birth.28
Factors in early life associated with more severe disease are
both risk factors for persisting disease, as well as for starting
ICS treatment. Thus, although subjects who received ICS
treatment by 2 years had more severe disease, the
propensity score was used to adjust for the severity of the
disease between 0 and 2 years of age. The logistic regression
analysis, with separate covariates could not adequately
adjust for severity of disease expected to modify possible
effect of ICS on CA. This is demonstrated by the modified
aOR resulting from further adjustment for the propensity for
ICS treatment (from aOR 2.04 (p ¼ 0.58) to 1.84,
(p ¼ 0.10)). In order to utilise the propensity score, there
must be a certain degree of overlap between the two groups
(children receiving ICS versus children not receiving ICS).
This was the case in the present study, and the propensity
approach underlined the result found with a conventional
analysis. Both models of analysis failed to demonstrate
decreased occurrence of CA at 10 years with early ICS
treatment.Strengths and limitations of the present study
The present study children were enroled in an unselected,
urban observational prospective cohort of healthy newborn
children. The nested case-control design (at 2 years)
enabled us to perform detailed investigations in children
with rBO and their healthy controls, but limits epidemiologic
observations on an unselected group of children at age 10
years. On the other hand, observational studies have an
overall advantage by including a broad population of
participants in contrast to randomized clinical trials select-ing children agreeing with sometimes rather narrow inclu-
sion criteria.29 For medical practise, the results from
longitudinal observational studies are reliable, especially
concerning prognosis and diagnosis.30
It may be argued that the present study includes a
limited number of patients using ICS before 2 years of age.
However, with a significance level of 5%, we had a statistical
power of 92% among rBO children to detect differences
in occurrence of CA at 10 years based upon the use of
ICS before 2 years of age, thus confirming our conclusion.
On the other hand, it should be underlined that the
present study is a non-randomized observational study
thus generating a hypothesis, which needs further confirma-
tion.
ICS treatment in children in the present study was
decided by the child’s own doctor, independent of the
study and without knowledge about study results. Also,
we have only the parents’ information obtained through
questionnaires and interviews of how much ICS had
been administrated, without quantitative assessment of
doses and treatment compliance over the 2 years, thus
reflecting ‘‘real-life’’ treatment situations. In observational
studies such as the present, it is not possible to separate
out the influence of factors associated with treatment
initiation from possible effects of the duration of treatment.
The use of propensity models is based on a number of
covariates related to the treatment assignment, and
when treatment assignment can be predicted accurately,
the estimates of the treatment effect obtained from
further analysis may be viewed as unbiased.22 Since the
use of the propensity score in the present observational
study introduces the element of quasi-randomization
treatment assignment can be viewed as ‘‘random’’ based
on the assumption that the two subjects were equally
likely to have been treated. The propensity modelling has
several advantages;31 it can be performed relatively
easily, there is no need to develop separate models or
adjustments for different outcomes, and simulation studies
have shown that when ‘‘adjusting’’ for potential confoun-
ders, the propensity score method is subject to less bias
compared with an incorrectly specified prognostic model.32
However, propensity scores can only allow for known sources
of selection bias, and the possibility of unknown sources of
bias cannot be ruled out, but this is also the case for the
standard analysis of observational studies. Although the
propensity modelling has not been used in studies in
respiratory medicine previously, this technique has been
reported in similar circumstances related to rheumatic
diseases22 and has been recommended by the United States
Food and Drug Administration (FDA) for use in nonrando-
mized trials, to compensate for the problem that patients
are not randomly assigned to treatment groups with equal
probability.33
In conclusion, a mean of 9 months treatment with ICS in
children with obstructive airways disease before the age of 2
years does not seem to affect the occurrence of asthma at
age 10 years, but larger intervention studies are needed to
confirm this finding. Although early use of ICS has been
shown to have short-term beneficial effects, the present
study does not support the hypothesis of improved long-term
prognosis for children treated with ICS for asthma symptoms
in early life.
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